ZN 012
Alternative Names: ZN-012Latest Information Update: 05 Oct 2023
At a glance
- Originator Zerion Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Oct 2023 ZN 012 is available for licensing as of 04 Oct 2023. https://www.zerion.eu/partnering (Zerion Pharma website, October 2023)
- 04 Oct 2023 Preclinical trials in Cancer in Denmark (PO) (Zerion Pharma pipeline, October 2023)
- 04 Oct 2023 Zerion Pharma plans to launch ZN 012, between 2025-2026 (Zerion Pharma pipeline, October 2023)